CohBar’s treatment of idiopathic pulmonary fibrosis, or IPF, was granted orphan status by the FDA, according to a post to the agency’s website. Reference Link
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CWBR:
- CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
- CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue